This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Maletzky, B. M. Articles by McFarland, B. Search for Related Content PubMed PubMed Citation Articles by Maletzky, B. M. Articles by McFarland, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Child Sexual Abuse Social Bookmarking                         What's this?

The Oregon depo-Provera Program: A Five-Year Follow-Up

Oregon Health Sciences University, marbar{at}easystreet.com

Arthur Tolan

Oregon Department of Corrections

Bentson McFarland

Oregon Health Sciences University, e-mail: marbar{at}easystreet.com

In 1999, the Oregon State Legislature, concerned about the risk certain sexual offenders might pose to their communities upon release from prison, enacted House Bill 2500. This bill required selected offenders to be evaluated prior to their release to determine whether medical treatment with medroxyprogesterone acetate (MPA), also known by its trade name of depo-Provera, was indicated to reduce their risk. The present study reviewed the first 275 men to be evaluated under this program from the years 2000 through 2004. Data were collected on diagnoses and outcome on three groups: men judged to need MPA who eventually went on to actually receive it; men recommended to receive MPA who, for a variety of reasons, did not receive the medication; and men deemed not to need MPA. Outcome measures included recidivism data, including reoffenses, parole violations, and reincarcerations, and whether these were sexual in nature. Data were also collected on employment and whether supervising officers believed the men in each group were doing well. Significant differences emerged among these three groups, with men actually receiving depo-Provera committing no new sexual offenses and also committing fewer overall offenses and violations compared to the other two groups. In addition, almost one third of men judged to need medication but who did not receive it committed a new offense and almost 60% of these were sexual in nature. While generalizations from these types of retrospective and partially subjective findings are inherently limited, the present study lends credence to the belief that, in selected offenders, anti-androgenic medication can be a valuable, if time-limited, addition to a cognitive and behavioral treatment program. Suggestions for more practical and far-reaching implementation of this adjunctive approach are offered.

Key Words: Anti-androgens • Depo-Provera • Medroyxprogesterone acetate • Paraphilias • Recidivism • Sexual offending

Sexual Abuse: A Journal of Research and Treatment, Vol. 18, No. 3, 303-316 (2006)
DOI: 10.1177/107906320601800308


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?